SCHEMBL4594682

SCHEMBL4594682

O=C1NCCC=C1N1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.41
HTT P42858 2/20 0.41
TP53 P04637 1/20 0.41
STAT3 P40763 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KMT2A Q03164 7/20 0.38
MEN1 O00255 6/20 0.38
ATM Q13315 2/20 0.38
LMNA P02545 2/20 0.38
APAF1 O14727 1/20 0.38
NPC1 O15118 1/20 0.38
TDP2 O95551 1/20 0.38
NSD2 O96028 1/20 0.38
RAB9A P51151 1/20 0.38
GALK1 P51570 1/20 0.38
BLM P54132 1/20 0.38
HKDC1 Q2TB90 1/20 0.38
NOD2 Q9HC29 1/20 0.38
ATG4B Q9Y4P1 1/20 0.38
ALDH1A1 P00352 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25704408 0.81 APAF1 (0.35) MAPTTP53SMN1; SMN2KMT2AMEN1
SCHEMBL2303232 0.77 ALDH1A1 (0.38) ALDH1A1
SCHEMBL2303095 0.74 ALDH1A1 (0.36) ALDH1A1
SCHEMBL9904083 0.73 APAF1 (0.34) MAPTTP53KMT2AMEN1LMNA
SCHEMBL1821124 0.69 MAPT (0.42) MAPTHTTTP53STAT3SMN1; SMN2
SCHEMBL23145857 0.68 MAPT (0.41) MAPTHTTTP53STAT3SMN1; SMN2
SCHEMBL16361771 0.68 MAPT (0.38) MAPTHTTTP53STAT3SMN1; SMN2
SCHEMBL18104502 0.68 MAPT (0.45) MAPTHTTTP53STAT3SMN1; SMN2
SCHEMBL7500812 0.67 MAPT (0.47) MAPTHTTTP53STAT3SMN1; SMN2
SCHEMBL9508287 0.66 MAPT (0.66) MAPTHTTTP53STAT3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107955002-B Preparation method of apixaban and intermediate thereof 上海博志研新药物技术有限公司 2019-12-24 CN claimed
CN-103342704-A Preparation method of Apixaban as anti-thrombotic drug GANSU HAOTIAN CHEMEXPRESS CO LTD 2013-10-09 CN claimed
EP-1937638-A1 METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS Elan Pharmaceuticals Inc. (US) 2008-07-02 EP claimed
WO-2007047306-A1 METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2007-04-26 WO claimed
US-20260132132-A1 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2026-05-14 US disclosed
US-20250353820-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS NOVARTIS AG (CH) 2025-11-20 US disclosed
US-12338220-B2 Antiviral pyrazolopiridinone compounds GILEAD SCIENCES, INC. (US) 2025-06-24 US disclosed
CN-120077042-A 3A,4,5, 6-tetrahydro-1H-pyrazolo [3,4-C ] pyridin-7 (7 AH) -one derivatives as factor XIIa inhibitors 卡尔维斯塔制药有限公司 2025-05-30 CN disclosed
WO-2024084217-A1 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-04-25 WO disclosed
US-20230365511-A1 Antiviral Pyrazolopiridinone Compounds NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365511-A1 Antiviral Pyrazolopiridinone Compounds NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20230365511-A1 Antiviral Pyrazolopiridinone Compounds NOVARTIS AG (CH) 2023-11-16 US disclosed
US-20040209863-A1 Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-21 US disclosed
EP-1467984-A2 SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO (3,4-C) PYRID-2-ONES Bristol-Myers Squibb Company (US) 2004-10-20 EP disclosed
WO-2004083177-A2 LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS BRYSTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed
WO-2004083174-A2 SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed
WO-2004083174-A2 SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed
US-20030181466-A1 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones BRISTOL-MYERS SQUIBB COMPANY 2003-09-25 US disclosed
WO-2003049681-A2 SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed
WO-2003049681-A2 SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO [3,4-C] PYRID-2-ONES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132132-A1 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS F11, F13B, F7 MAPT 4849/4885HTT 4780/4885TP53 4868/4885
US-20040209863-A1 Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors TFPI, SPINT2, TMPRSS4 MAPT 4593/4885HTT 3663/4885TP53 3633/4885
US-20250353820-A1 ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS ZC3HAV1, TYMP, ZC3HAV1L MAPT 1900/4885HTT 3477/4885TP53 1487/4885
US-20030181466-A1 Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones TFPI, TFPI2, F2 MAPT 4714/4885HTT 4039/4885TP53 4614/4885
US-20230365511-A1 Antiviral Pyrazolopiridinone Compounds ZC3HAV1, ZC3HAV1L, RPL35 MAPT 2766/4885HTT 3726/4885TP53 679/4885
US-12338220-B2 Antiviral pyrazolopiridinone compounds ZC3HAV1, ZC3HAV1L, RPL35 MAPT 2766/4885HTT 3726/4885TP53 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.